

Europass curriculum vitae

Informazioni personali

Nome e cognome

Simone Cazzaniga

Indirizzo

Omissis

Telefono

E-mail

Cittadinanza

Italiana

Data di nascita

22/09/1981

Sesso

Maschile

Posizione ricoperta

Analisi e gestione dati

Esperienza professionale

Date

Maggio 2006 - presente

Posizione ricoperta

Responsabile analisi e gestione dati

Nome e indirizzo del datore di lavoro

Centro Studi GISED - Via Torino 13, 24128 Bergamo (IT)

Principali attività e responsabilità

Statistica epidemiologica, coordinamento studi clinici, analisi di immagini biomediche, modellazione matematica, creazione di sistemi elettronici di raccolta dati

Attività o settore

Medicina - Dermatologia

Date

Gennaio 2015 - presente

Posizione ricoperta

Epidemiologo, assistente scientifico

Nome e indirizzo del datore di lavoro

Ospedale Universitario Inselspital - Freiburgstrasse 34, 3010 Berna (CH)

Principali attività e responsabilità

Statistica epidemiologica, coordinamento studi clinici, modellazione matematica

Attività o settore

Medicina - Dermatologia

Istruzione e formazione

Data

Novembre 2019

Certificato o diploma ottenuto

Dottorato in Scienze Biomediche

Principali materie/competenze professionali apprese

Statistica epidemiologica - Algoritmi di data mining

Analisi mediante mappe semantiche - Revisioni sistematiche e meta-analisi

Nome e tipo d'istituto di istruzione

Università di Berna (CH), Graduate School for Cellular and Biomedical Sciences

Data

Dicembre 2005

Certificato o diploma ottenuto

Master M.A.M.I.

Principali materie/competenze professionali apprese	Programmazione in C, C++, MATLAB - Costruzione ed analisi di modelli numerici Elaborazione di immagini e computer vision - Statistica applicata Analisi armonica - Teoria dei codici e Crittografia
Nome e tipo d'istituto di istruzione	Università degli studi di Milano Bicocca (IT), dipartimento di Matematica ed applicazioni
Data	Novembre 2004
Certificato o diploma ottenuto	Laurea in Matematica
Principali materie/competenze professionali apprese	Analisi superiore - Istituzioni di fisica - Calcolo delle probabilità e Statistica Matematica computazionale - Analisi numerica - Laboratorio di calcolo Ottimizzazione
Nome e tipo d'istituto di istruzione	Università degli studi di Milano Bicocca (IT), dipartimento di Matematica ed applicazioni
Data	Luglio 2001
Certificato o diploma ottenuto	Maturità scientifica
Nome e tipo d'istituto di istruzione	Liceo scientifico M.G. Agnesi, Merate – Lecco (IT)

Competenze personali

Madrelingua

Italiana

Altra lingua

Autovalutazione

Livello europeo ()*

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione	Produzione orale	Produzione scritta
C1	C1	C1	C1	C1

() Quadro comune europeo di riferimento per le lingue*

Inglese

Competenze comunicative

Buona capacità di cooperazione, maturata attraverso molteplici attività di gruppo sia in ambito universitario che lavorativo, e buona capacità di gestione individuale.

Competenze organizzative e gestionali

Coordinamento di studi clinici e pianificazione delle attività correlate.

Competenze professionali

Statistica epidemiologica; modellazione matematica; machine learning; implementazione di algoritmi per l'estrazione e l'analisi dei dati; analisi di immagini biomediche; creazione di sistemi elettronici di raccolta dati.

Competenze informatiche

Sistemi operativi: Windows, Linux
Pacchetti applicativi: Microsoft Office, LibreOffice
Pacchetti statistici: SPSS, MATLAB, R
Linguaggi di programmazione: C, C++, FORTRAN, BASIC, MATLAB
Linguaggi Web: PHP, HTML, CSS, JavaScript

Altre competenze

Esperienza in ambito di web-publishing.

Patente di guida


B

Ulteriori informazioni

Lista delle pubblicazioni

1. Pezzolo E, Cazzaniga S, Di Leo S, Naldi L, PsoReal Study Group. Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience. *J Eur Acad Dermatol Venereol.* 2022;36(7):e534-e537. doi:10.1111/jdv.17997
2. Radonjic-Hoesli S, Martignoni Z, Cazzaniga S, et al. Characteristics of Dermatological Patients With Blood Eosinophilia: A Retrospective Analysis of 453 Patients. *J Allergy Clin Immunol Pract.* 2022;10(5):1229-1237.e8. doi:10.1016/j.jaip.2022.02.018
3. Piaserico S, Gisondi P, Cazzaniga S, Di Leo S, Naldi L. Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. *J Invest Dermatol.* 2022;142(2):355-363.e7. doi:10.1016/j.jid.2021.04.036
4. Cazzaniga S, Naldi L. Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic. *Br J Dermatol.* 2022;186(1):7-8. doi:10.1111/bjd.20776
5. Seyed Jafari SM, Lieberherr S, Cazzaniga S, Beltraminelli H, Haneke E, Hunger RE. Melanoma of the Nail Apparatus: An Analysis of Patients' Survival and Associated Factors. *Dermatology.* 2022;238(1):156-160. doi:10.1159/000514493
6. Seyed Jafari SM, Cazzaniga S, Bossart S, et al. Efficacy Assessment of the High-Frequency High-Intensity Focused Ultrasound as a New Treatment for Actinic Keratosis. *Dermatology.* 2022;238(4):662-667. doi:10.1159/000520536
7. Distel J, Cazzaniga S, Seyed Jafari SM, et al. Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience. *Dermatology.* 2022;238(2):267-275. doi:10.1159/000515763
8. Bossart S, Cazzaniga S, Willenberg T, et al. Reliability Assessment and Validation of the Skin Hyperpigmentation Index Compared to the Physician Global Assessment Score. *Dermatology.* 2022;238(4):688-691. doi:10.1159/000520753
9. Imstepf V, Cazzaniga S, Beltraminelli H, Borradori L, Feldmeyer L. Brunsting-Perry pemphigoid: A retrospective case series of a frequently unrecognized condition. *J Am Acad Dermatol.* 2021;85(5):1324-1326. doi:10.1016/j.jaad.2020.10.029
10. Gisondi P, Cazzaniga S, Di Leo S, et al. Impact of the COVID-19 pandemic on melanoma diagnosis. *J Eur Acad Dermatol Venereol.* 2021;35(11):e714-e715. doi:10.1111/jdv.17493
11. Ingordo V, Feci L, Cazzaniga S, Naldi L, Ingordo I, Sirna R. Measuring the horizontal and vertical growth rates of superficial spreading melanoma: a pilot study with sequential digital dermoscopy. *Ital J Dermatol Venerol.* 2021;156(4):473-478. doi:10.23736/S2784-8671.19.06489-7
12. Gisondi P, Bellinato F, Piaserico S, Di Leo S, Cazzaniga S, Naldi L. Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. *Dermatol Ther (Heidelb).* 2021;11(4):1333-1343. doi:10.1007/s13555-021-00555-3
13. Cazzaniga S, Pezzolo E, Garcovich S, Naldi L, IRHIS Study Group. Late-onset hidradenitis suppurativa: A cluster analysis of the National Italian Registry IRHIS. *J Am Acad Dermatol.* 2021;85(1):e29-e32. doi:10.1016/j.jaad.2021.02.075
14. Borradori L, Vinay K, Bishnoi A, Cazzaniga S, Joly P. How to diagnose bullous pemphigoid and its variants: the question is still open. *J Eur Acad Dermatol Venereol.* 2021;35(7):e434-e435. doi:10.1111/jdv.17214
15. van Amerongen CCA, Ofenloch RF, Cazzaniga S, et al. Skin exposure to scented products used in daily life and fragrance contact allergy in the European general

- population - The EDEN Fragrance Study. *Contact Dermatitis*. 2021;84(6):385-394. doi:10.1111/cod.13807
16. Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton PG, Naldi L. Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? *J Eur Acad Dermatol Venereol*. 2021;35(6):e355-e357. doi:10.1111/jdv.17175
 17. Gisondi P, Di Leo S, Bellinato F, Cazzaniga S, Piaserico S, Naldi L. Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. *Dermatol Ther (Heidelb)*. 2021;11(3):695-705. doi:10.1007/s13555-021-00526-8
 18. Pezzolo E, Ciampichini R, Cazzaniga S, Sampietro G, Zucchi A, Naldi L. Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy. *Arch Dermatol Res*. 2021;313(4):255-261. doi:10.1007/s00403-020-02101-1
 19. Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of Hidradenitis Suppurativa Phenotypes: A Multidimensional Latent Class Analysis of the National Italian Registry IRHIS. *J Invest Dermatol*. 2021;141(5):1236-1242.e1. doi:10.1016/j.jid.2020.08.032
 20. Zohdy M, Cazzaniga S, Nievergelt H, et al. Inter-Observer and Intra-Observer Variations in the Assessment of Epithelial Dysplasia in Oral Lichenoid Diseases. *Dermatopathology (Basel)*. 2021;8(2):84-88. doi:10.3390/dermatopathology8020013
 21. Rohner MH, Thormann K, Cazzaniga S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. *Allergy*. 2021;76(4):1268-1270. doi:10.1111/all.14664
 22. Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. *J Allergy Clin Immunol*. 2021;147(2):558-560.e1. doi:10.1016/j.jaci.2020.10.032
 23. Damiani G, Cazzaniga S, Naldi L, PsoReal Study Group. Use of fumaric acid derivatives in Italian reference centers for psoriasis. *Ital J Dermatol Venereol*. 2021;156(1):36-41. doi:10.23736/S2784-8671.18.06032-7
 24. Damiani G, Cazzaniga S, Naldi L, PsoReal Study Group. Use of fumaric acid derivatives in Italian reference centers for psoriasis. *Ital J Dermatol Venereol*. 2021;156(1):36-41. doi:10.23736/S0392-0488.18.06032-7
 25. Bossart S, Ramelet AA, Willenberg T, et al. Skin Hyperpigmentation Index Facilitating Quantification of Hyperpigmentation in Clinical Practice. *Dermatology*. 2021;237(3):486-488. doi:10.1159/000509160
 26. Ingordo V, Cazzaniga S, Naldi L, et al. Atopic dermatitis in young adult Italian males: persistent and adult-onset varieties did not clinically differ, as for allergological variables. *G Ital Dermatol Venereol*. 2020;155(6):724-732. doi:10.23736/S0392-0488.18.06239-9
 27. Bossart S, Willenberg T, Ramelet AA, Cazzaniga S, Hunger RE, Seyed Jafari SM. The skin hyperpigmentation index: An objective method of measuring the intensity of hyperpigmentation after sclerotherapy. *Phlebology*. 2020;35(10):833-835. doi:10.1177/0268355520941359
 28. Haefliger S, Sitaru S, Cazzaniga S, et al. Diagnostic performance of direct immunofluorescence microscopy studies by biopsy sites in autoimmune subepidermal blistering dermatoses: a prospective study. *Br J Dermatol*. 2020;183(5):970-972. doi:10.1111/bjd.19305
 29. Piaserico S, Gisondi P, Cazzaniga S, Naldi L. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. *Am J Clin Dermatol*. 2020;21(5):749-751. doi:10.1007/s40257-020-00552-w
 30. Damiani G, Manganoni A, Cazzaniga S, Naldi L, OncoSkin working group. Survey of

- cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. *G Ital Dermatol Venereol*. 2020;155(5):658-661. doi:10.23736/S0392-0488.18.06033-9
31. Naldi L, Cazzaniga S. Research Techniques Made Simple: Latent Class Analysis. *J Invest Dermatol*. 2020;140(9):1676-1680.e1. doi:10.1016/j.jid.2020.05.079
 32. Naldi L, Cazzaniga S. More on Covid-19 in Immune-Mediated Inflammatory Diseases. *N Engl J Med*. 2020;383(8):795-796. doi:10.1056/NEJMc2018011
 33. Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. *Br J Dermatol*. 2020;183(2):373-374. doi:10.1111/bjd.19158
 34. Gadaldi K, Cazzaniga S, Feldmeyer L, Krause E, Günthert AR, Beltraminelli H. Genital lichen sclerosus in women: a histopathological analysis of 38 criteria. *J Eur Acad Dermatol Venereol*. 2020;34(8):e418-e420. doi:10.1111/jdv.16368
 35. Bossart S, Cazzaniga S, Willenberg T, et al. Skin hyperpigmentation index: a new practical method for unbiased automated quantification of skin hyperpigmentation. *J Eur Acad Dermatol Venereol*. 2020;34(7):e334-e336. doi:10.1111/jdv.16312
 36. Lieberherr S, Cazzaniga S, Haneke E, Hunger RE, Seyed Jafari SM. Melanoma of the nail apparatus: a systematic review and meta-analysis of current challenges and prognosis. *J Eur Acad Dermatol Venereol*. 2020;34(5):967-976. doi:10.1111/jdv.16121
 37. Virgili A, Borghi A, Cazzaniga S, et al. Gender differences in genital lichen sclerosus: data from a multicenter Italian study on 729 consecutive cases. *G Ital Dermatol Venereol*. 2020;155(2):155-160. doi:10.23736/S0392-0488.17.05819-9
 38. Ingordo V, Feci L, Cazzaniga S, Naldi L, Ingordo I, Sirna R. Measuring the horizontal and vertical growth rates of superficial spreading melanoma: a pilot study with sequential digital dermoscopy. *G Ital Dermatol Venereol*. Published online March 3, 2020. doi:10.23736/S0392-0488.19.06489-7
 39. Simon D, Yousefi S, Cazzaniga S, et al. Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study. *Allergy*. 2020;75(3):669-672. doi:10.1111/all.13950
 40. Feldmeyer L, Suter VG, Oeschger C, et al. Oral lichen planus and oral lichenoid lesions - an analysis of clinical and histopathological features. *J Eur Acad Dermatol Venereol*. 2020;34(2):e104-e107. doi:10.1111/jdv.15981
 41. Stanganelli I, Naldi L, Cazzaniga S, et al. Sunburn-related variables, secular trends of improved sun protection and short-term impact on sun attitude behavior in Italian primary schoolchildren: Analysis of the educational campaign "Il Sole Amico" ("The sun as a friend"). *Medicine (Baltimore)*. 2020;99(1):e18078. doi:10.1097/MD.00000000000018078
 42. Lehmann M, Cazzaniga S, Simon D, Perruchoud D, Borradori L, Rammimair A. Patterns among Patients with Chronic Pruritus: A Retrospective Analysis of 170 Patients. *Acta Derm Venerol*. Published online 2020:0. doi:10.2340/00015555-3405
 43. Heidemeyer K, Feldmeyer L, Raeber I, et al. Successful Treatment of Iatrogenic Cutaneous Siderosis with Pigment Lasers: A Retrospective Study in 15 Consecutive Patients. *Acta dermato-venereologica*. 2020;100(10):adv00148.
 44. Cazzaniga S, Wiedmer C, Frangež , et al. Association of Vascular Endothelial Growth Factor Subtypes with Melanoma Patients' Characteristics and Survival: A Semantic Connectivity Map Analysis. *Acta Derm Venerol*. 2020;100(1):1-2. doi:10.2340/00015555-3374
 45. Antiga E, Bonciolini V, Cazzaniga S, et al. Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease. *BioMed Research International*. 2019;2019:1-7. doi:10.1155/2019/6307035

46. Naldi L, Cazzaniga S. Reply to: "Comment on 'Mobile teledermatology for melanoma detection: Assessment of validity in the framework of a population-based skin cancer awareness campaign in northern Italy.'" *J Am Acad Dermatol*. 2019;81(6):e177. doi:10.1016/j.jaad.2019.06.1290
47. Cazzaniga S, Anzengruber F, Augustin M, et al. Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. *J Eur Acad Dermatol Venereol*. 2019;33(12):2313-2318. doi:10.1111/jdv.15983
48. Bettoli V, Cazzaniga S, Scuderi V, et al. Hidradenitis suppurativa epidemiology: from the first Italian registry in 2009 to the most recent epidemiology updates - Italian Registry Hidradenitis Suppurativa project 2. *J Eur Acad Dermatol Venereol*. 2019;33 Suppl 6:4-6. doi:10.1111/jdv.15826
49. Damiani G, Cazzaniga S, Conic RRZ, et al. Pruritus characteristics in a large Italian cohort of psoriatic patients. *J Eur Acad Dermatol Venereol*. 2019;33(7):1316-1324. doi:10.1111/jdv.15539
50. Cazzaniga S, Castelli E, Di Landro A, et al. Mobile teledermatology for melanoma detection: Assessment of the validity in the framework of a population-based skin cancer awareness campaign in northern Italy. *Journal of the American Academy of Dermatology*. 2019;81(1):257-260. doi:10.1016/j.jaad.2019.02.036
51. Pezzolo E, Cazzaniga S, Colombo P, Chatenoud L, Naldi L. Psoriasis Incidence and Lifetime Prevalence: Suggestion for a Higher Mortality Rate in Older Age-classes among Psoriatic Patients Compared to the General Population in Italy. *Acta Derm Venereol*. 2019;99(4):400-403. doi:10.2340/00015555-3130
52. Pacifico A, Iacovelli P, Damiani G, et al. "High dose" vs. "medium dose" UVA1 phototherapy in Italian patients with severe atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2019;33(4):718-724. doi:10.1111/jdv.15362
53. Ofenloch RF, Schuttelaar ML, Svensson Å, et al. Socioeconomic Status and the Prevalence of Skin and Atopic Diseases in Five European Countries. *Acta Derm Venereol*. 2019;99(3):309-314. doi:10.2340/00015555-3082
54. Stillhard A, Cazzaniga S, Borradori L, Beltraminelli H. Pushing and loss of elastic fibers are highly specific for melanoma and rare in melanocytic nevi. *Arch Dermatol Res*. 2019;311(2):99-107. doi:10.1007/s00403-018-1885-x
55. Cazzaniga S, Naldi L, Virgili A, et al. An original exploration of genital lichen sclerosis: the semantic connectivity map. *J Eur Acad Dermatol Venereol*. 2019;33(2):e59-e62. doi:10.1111/jdv.15191
56. Pelloni L, Cazzaniga S, Naldi L, Borradori L, Mainetti C. Emergency Consultations in Dermatology in a Secondary Referral Hospital in Southern Switzerland: A Prospective Cross-Sectional Analysis. *Dermatology*. 2019;235(3):243-249. doi:10.1159/000498850
57. Fröhlich SM, Cazzaniga S, Kaufmann LS, Hunger RE, Seyed Jafari SM. A Retrospective Cohort Study on Patients with Lentigo Maligna Melanoma. *Dermatology*. 2019;235(4):340-345. doi:10.1159/000499689
58. Seyed Jafari SM, Cazzaniga S, Hunger RE. Photodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysis. *G Ital Dermatol Venereol*. 2018;153(6):827-832. doi:10.23736/S0392-0488.18.05977-1
59. Cazzaniga S, Scerri L, Gabbud JP, Arenberger P, Borradori L, Naldi L. Factors influencing sessions' and speakers' evaluation: an analysis of seven consecutive European Academy of Dermatology and Venereology congress editions. *J Eur Acad Dermatol Venereol*. 2018;32(12):2307-2313. doi:10.1111/jdv.15178
60. Amani Uwajeni A, Mshana J, Kiprono S, et al. Acne at the Regional Dermatology Training Centre (RDTC), Tanzania: clinical, social and demographic characteristics of

- patients with focus on severity factors. *J Eur Acad Dermatol Venereol*. 2018;32(12):e451-e453. doi:10.1111/jdv.15041
61. Seyed Jafari SM, Wiedmer C, Cazzaniga S, et al. Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. St-Pierre Y, ed. *PLoS ONE*. 2018;13(11):e0207019. doi:10.1371/journal.pone.0207019
 62. Cazzaniga S, Naldi L, Damiani G, et al. Validation of a visual-aided questionnaire for the self-assessment of hidradenitis suppurativa. *J Eur Acad Dermatol Venereol*. 2018;32(11):1993-1998. doi:10.1111/jdv.15050
 63. Garcia-Doval I, Descalzo MA, Mason KJ, et al. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. *Br J Dermatol*. 2018;179(4):863-871. doi:10.1111/bjd.16715
 64. Cazzaniga S, Ballmer-Weber BK, Gräni N, et al. Chronic hand eczema: A prospective analysis of the Swiss CARPE registry focusing on factors associated with clinical and quality of life improvement. *Contact Dermatitis*. 2018;79(3):136-148. doi:10.1111/cod.13041
 65. Benzaquen M, Borradori L, Cazzaniga S, Berbis P, Feldmeyer L. Reply to: "Bullous pemphigoid and diabetes mellitus: Are we missing the larger picture?" *J Am Acad Dermatol*. 2018;79(2):e29-e30. doi:10.1016/j.jaad.2018.03.049
 66. Schuttelaar MLA, Ofenloch RF, Bruze M, et al. Prevalence of contact allergy to metals in the European general population with a focus on nickel and piercings: The EDEN Fragrance Study. *Contact Dermatitis*. 2018;79(1):1-9. doi:10.1111/cod.12983
 67. Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. *J Am Acad Dermatol*. 2018;78(6):1090-1096. doi:10.1016/j.jaad.2017.12.038
 68. Thomi R, Cazzaniga S, Seyed Jafari SM, Schlapbach C, Hunger RE. Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes: A Semantic Map Analysis. *JAMA Dermatol*. 2018;154(5):592-595. doi:10.1001/jamadermatol.2018.0141
 69. Svensson A, Ofenloch RF, Bruze M, et al. Prevalence of skin disease in a population-based sample of adults from five European countries. *Br J Dermatol*. 2018;178(5):1111-1118. doi:10.1111/bjd.16248
 70. Naldi L, Falgheri G, De Bitonto A, et al. Perception of ABC (asymmetry, borders, and color) parameters in the screening for melanoma: Model exercise with experienced dermatologists. *J Am Acad Dermatol*. 2018;78(5):996-998. doi:10.1016/j.jaad.2017.12.035
 71. Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L. Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. *J Am Acad Dermatol*. 2018;78(4):806-808. doi:10.1016/j.jaad.2017.11.024
 72. Wilke A, Bollmann U, Cazzaniga S, et al. The implementation of knowledge dissemination in the prevention of occupational skin diseases. *J Eur Acad Dermatol Venereol*. 2018;32(3):449-458. doi:10.1111/jdv.14653
 73. Busard CI, Cohen AD, Wolf P, et al. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSUNET registries. *J Eur Acad Dermatol Venereol*. 2018;32(2):245-253. doi:10.1111/jdv.14583
 74. Cazzaniga S, Apfelbacher C, Diepgen T, et al. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. *Br J Dermatol*. 2018;178(1):229-237. doi:10.1111/bjd.15660
 75. Seyed Jafari SM, Knüsel E, Cazzaniga S, Hunger RE. A Retrospective Cohort Study

- on Patients with Hidradenitis Suppurativa. *Dermatology*. 2018;234(1-2):71-78. doi:10.1159/000488344
76. Nacoti M, Cazzaniga S, Colombo G, et al. Postoperative complications in cirrhotic pediatric deceased donor liver transplantation: Focus on transfusion therapy. *Pediatr Transplant*. 2017;21(8). doi:10.1111/petr.13020
 77. Naldi L, Cazzaniga S, Di Mercurio M, Grossi E, Addis A, Psocare study centres. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. *Br J Dermatol*. 2017;176(5):1331-1338. doi:10.1111/bjd.15234
 78. Davila-Seijo P, Garcia-Doval I, Naldi L, et al. Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. *Acta Derm Venereol*. 2017;97(4):516-518. doi:10.2340/00015555-2586
 79. Virgili A, Borghi A, Cazzaniga S, et al. New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases. *J Eur Acad Dermatol Venereol*. 2017;31(4):699-704. doi:10.1111/jdv.13867
 80. Bencini PL, Guida S, Cazzaniga S, et al. Risk factors for recurrence after successful treatment of warts: the role of smoking habits. *J Eur Acad Dermatol Venereol*. 2017;31(4):712-716. doi:10.1111/jdv.14086
 81. Perruchoud DL, Cazzaniga S, Heidemeyer K, et al. Treatment of sporadic port-wine stains: a retrospective review of 17 cases consecutively treated by pulsed sequential dual wavelength 595 and 1064 nm laser. *J Eur Acad Dermatol Venereol*. 2017;31(3):557-563. doi:10.1111/jdv.13975
 82. Garcia-Doval I, Cohen AD, Cazzaniga S, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. *J Am Acad Dermatol*. 2017;76(2):299-308.e16. doi:10.1016/j.jaad.2016.07.039
 83. Schaffer C, Buclin T, Jornayvaz FR, et al. Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. *Dermatology*. 2017;233(5):401-403. doi:10.1159/000480498
 84. Lieberherr S, Seyed Jafari SM, Cazzaniga S, et al. Evaluation of the National Skin Cancer Campaign: a Swiss experience of Euromelanoma. *Swiss Med Wkly*. 2017;147:w14511. doi:10.4414/smw.2017.14511
 85. Dragoni F, Conti R, Cazzaniga S, et al. No Association between Vitiligo and Obesity: A Case-Control Study. *Med Princ Pract*. 2017;26(5):421-426. doi:10.1159/000481436
 86. Di Landro A, Cazzaniga S, Cusano F, et al. Adult female acne and associated risk factors: Results of a multicenter case-control study in Italy. *J Am Acad Dermatol*. 2016;75(6):1134-1141.e1. doi:10.1016/j.jaad.2016.06.060
 87. Glauser S, Rutz M, Cazzaniga S, Hegyi I, Borradori L, Beltraminelli H. Diagnostic value of immunohistochemistry on formalin-fixed, paraffin-embedded skin biopsy specimens for bullous pemphigoid. *Br J Dermatol*. 2016;175(5):988-993. doi:10.1111/bjd.14686
 88. Bettoli V, Pasquinucci S, Caracciolo S, et al. The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. *J Eur Acad Dermatol Venereol*. 2016;30(11):1965-1970. doi:10.1111/jdv.13687
 89. Cazzaniga S, Castelli E, Di Landro A, Zucchi A, Naldi L. [Development of a teledermatology system for the melanoma diagnosis. The pilot experience of the project Clicca il neo]. *Recenti Prog Med*. 2016;107(8):440-443. doi:10.1701/2332.25070
 90. Kaufmann RA, Oberholzer PA, Cazzaniga S, Hunger RE. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. *Eur J*

Dermatol. 2016;26(3):265-270. doi:10.1684/ejd.2016.2758

91. Cazzaniga S, Naldi L, Lecchi S, et al. A pilot study on the incidence of severe photosensitivity reactions leading to hospitalization linked to topical ketoprofen and other medications in selected European regions. *Pharmacol Res Perspect.* 2016;4(3):e00225. doi:10.1002/prp2.225
92. Gritti P, Cazzaniga S, Castioni CA, et al. Variability by country in the European Neuroanaesthesia and Critical Care Interest Group subarachnoid haemorrhage survey. *Eur J Anaesthesiol.* 2016;33(5):387-390. doi:10.1097/EJA.0000000000000368
93. Cazzaniga S, Ballmer-Weber BK, Gräni N, et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. *J Eur Acad Dermatol Venereol.* 2016;30(4):628-637. doi:10.1111/jdv.13479
94. Christoph S, Cazzaniga S, Hunger R, Naldi L, Borradori L, Oberholzer P. Ultraviolet radiation protection and skin cancer awareness in recreational athletes: a survey among participants in a running event. *Swiss Med Wkly.* Published online March 21, 2016. doi:10.4414/smw.2016.14297
95. Diepgen TL, Ofenloch R, Bruze M, et al. Colophony as a marker for fragrance allergy in the general European population. *Br J Dermatol.* 2016;174(3):695-696. doi:10.1111/bjd.14297
96. Naldi L, Cazzaniga S. Prediction of high total naevus count to estimate melanoma risk. We need more, don't we? *Br J Dermatol.* 2016;174(2):261-262. doi:10.1111/bjd.14334
97. Diphhoorn J, Cazzaniga S, Gamba C, et al. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. *Pharmacoepidemiol Drug Saf.* 2016;25(2):196-203. doi:10.1002/pds.3937
98. Diepgen TL, Naldi L, Bruze M, et al. Prevalence of Contact Allergy to p-Phenylenediamine in the European General Population. *J Invest Dermatol.* 2016;136(2):409-415. doi:10.1016/j.jid.2015.10.064
99. Diepgen TL, Ofenloch RF, Bruze M, et al. Prevalence of contact allergy in the general population in different European regions. *Br J Dermatol.* 2016;174(2):319-329. doi:10.1111/bjd.14167
100. Grossi E, Cazzaniga S, Crotti S, et al. The constellation of dietary factors in adolescent acne: a semantic connectivity map approach. *J Eur Acad Dermatol Venereol.* 2016;30(1):96-100. doi:10.1111/jdv.12878
101. Bettoli V, Naldi L, Cazzaniga S, et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. *Br J Dermatol.* 2016;174(1):195-197. doi:10.1111/bjd.13864
102. Naldi L, Cazzaniga S. Author's Reply to the Response to the Commentary of Naldi and Cazzaniga Entitled "Are All Screening Programmes Created Equal? The Case of Melanoma." *Dermatology.* 2016;232(3):384. doi:10.1159/000444708
103. Diepgen TL, Ofenloch R, Bruze M, et al. Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study. *Br J Dermatol.* 2015;173(6):1411-1419. doi:10.1111/bjd.14151
104. Cazzaniga S, Lecchi S, Bruze M, et al. Development of a clinical score system for the diagnosis of photoallergic contact dermatitis using a consensus process: item selection and reliability. *J Eur Acad Dermatol Venereol.* 2015;29(7):1376-1381. doi:10.1111/jdv.12879
105. Gisondi P, Cazzaniga S, Chimenti S, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. *Br J Dermatol.* 2015;172(6):1613-1620. doi:10.1111/bjd.13539
106. Gritti P, Castioni CA, Cazzaniga S, Bilotta F. Perioperative management of patients

with acute subarachnoid hemorrhage. Do Italians think differently? *Minerva Anesthesiol.* 2015;81(4):466-467.

107. Parlar B, Blazek C, Cazzaniga S, et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. *J Eur Acad Dermatol Venereol.* 2015;29(3):549-554. doi:10.1111/jdv.12627
108. Naldi L, Cazzaniga S. Are All Screening Programmes Created Equal? The Case of Melanoma. *Dermatology.* 2015;231(4):294-296. doi:10.1159/000439403
109. Gritti P, Lanterna LA, Rotasperti L, et al. Clinical evaluation of hyponatremia and hypovolemia in critically ill adult neurologic patients: contribution of the use of cumulative balance of sodium. *J Anesth.* 2014;28(5):687-695. doi:10.1007/s00540-014-1814-x
110. Gamba C, Schroeder J, Citterio A, et al. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia]. *Recenti Prog Med.* 2014;105(10):379-384. doi:10.1701/1626.17670
111. Cazzaniga S, Conti A, Naldi L, Psoriasis Emilia Romagna Study Group. Comments on "Diet and psoriasis, Part I: Impact of weight loss interventions." *J Am Acad Dermatol.* 2014;71(4):829. doi:10.1016/j.jaad.2014.05.072
112. Piaserico S, Cazzaniga S, Chimenti S, et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. *J Am Acad Dermatol.* 2014;70(2):257-262.e3. doi:10.1016/j.jaad.2013.10.019
113. Naldi L, Cazzaniga S, Gonçalo M, et al. Prevalence of self-reported skin complaints and avoidance of common daily life consumer products in selected European Regions. *JAMA Dermatol.* 2014;150(2):154-163. doi:10.1001/jamadermatol.2013.7932
114. Cazzaniga S, Lo Scocco G, Schincaglia E, et al. Double-blind, within-patient, randomized, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar psoriasis. *J Dermatolog Treat.* 2014;25(1):26-29. doi:10.3109/09546634.2012.681359
115. Naldi L, Conti A, Cazzaniga S, et al. Diet and physical exercise in psoriasis: A randomized controlled trial. *British Journal of Dermatology.* 2014;170(3):634-642.
116. Ingordo V, Cazzaniga S, Raone B, et al. Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: A multicenter Italian study. *Dermatology.* 2014;228(3):240-249.
117. Ingordo V, Cazzaniga S, Medri M, et al. To what extent is quality of life impaired in vitiligo? A multicenter study on Italian patients using the dermatology life quality index. *Dermatology.* 2014;229(3):240-247.
118. Cazzaniga S, Lo Scocco G, Schincaglia E, et al. Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar pustulosis. *Dermatology.* 2014;228(2):166-171. doi:10.1159/000357221
119. Bencini PL, Cazzaniga S, Galimberti MG, Zane C, Naldi L. Variables affecting clinical response to treatment of facial port-wine stains by flash lamp-pumped pulsed dye laser: The importance of looking beyond the skin. *Lasers in Medical Science.* 2014;29(4):1365-1370.
120. Gelardi M, Iannuzzi L, Greco Miani A, et al. Double-blind placebo-controlled randomized clinical trial on the efficacy of Aerosal in the treatment of sub-obstructive adenotonsillar hypertrophy and related diseases. *Int J Pediatr Otorhinolaryngol.* 2013;77(11):1818-1824. doi:10.1016/j.ijporl.2013.08.013
121. Naldi L, Cazzaniga S. [Dermatology: experience with the disease registry for the treatment of psoriasis]. *Recenti Prog Med.* 2013;104(6):236-240. doi:10.1701/1295.14323
122. Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with

initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. *J Eur Acad Dermatol Venereol.* 2013;27(1):e30-41. doi:10.1111/j.1468-3083.2012.04450.x

123. Suppa M, Cazzaniga S, Fagnoli MC, Naldi L, Peris K. Knowledge, perceptions and behaviours about skin cancer and sun protection among secondary school students from Central Italy. *Journal of the European Academy of Dermatology and Venereology.* 2013;27(5):571-579.
124. Cortés B, Khelifa E, Clivaz L, et al. Mortality rate in bullous pemphigoid: A retrospective monocentric cohort study. *Dermatology.* 2013;225(4):320-325.
125. Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. *J Am Acad Dermatol.* 2012;67(6):1129-1135. doi:10.1016/j.jaad.2012.02.018
126. Naldi L, Cazzaniga S, Borradori L. Bullous pemphigoid: simple measures for a complex disease. *J Invest Dermatol.* 2012;132(8):1948-1950. doi:10.1038/jid.2012.178
127. Nacoti M, Cazzaniga S, Lorusso F, et al. The impact of perioperative transfusion of blood products on survival after pediatric liver transplantation. *Pediatr Transplant.* 2012;16(4):357-366. doi:10.1111/j.1399-3046.2012.01674.x
128. Ingordo V, Cazzaniga S, Gentile C, Iannazzone SS, Cusano F, Naldi L. Dermatology Life Quality Index score in vitiligo patients: A pilot study among young Italian males. *Giornale Italiano di Dermatologia e Venereologia.* 2012;147(1):83-90.
129. Bencini PL, Cazzaniga S, Turlaki A, Galimberti MG, Naldi L. Removal of tattoos by Q-switched laser: Variables influencing outcome and sequelae in a large cohort of treated patients. *Archives of Dermatology.* 2012;148(12):1364-1369.
130. Cazzaniga S, Sassi F, Mercuri SR, Naldi L. Prediction of clinical response to excimer laser treatment in vitiligo by using neural network models. *Dermatology.* 2009;219(2):133-137. doi:10.1159/000225934
131. Sassi F, Cazzaniga S, Tessari G, et al. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. *Br J Dermatol.* 2008;159(5):1186-1191. doi:10.1111/j.1365-2133.2008.08793.x

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Luogo e data

Milano, 08/07/2022

Firma

Firma oscurata ai sensi delle
Linee Guida del Garante per la
Privacy